PYRAZOLYLAMINOPYRIDINES AS INHIBITORS OF FAK
The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 11 , R 12 , R 13 , Q, Z, and p are as described herein. Compounds of the present invention are useful for the treatment of cancers.
1 . The method of inhibiting FAK activity in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of the compound:
2-[(5-Chloro-2-{[3-methyl-1-(1-methylethyl)-1H-pyrazol-5-yl]amino}-4-pyridinyl)amino]-N-(methyloxy)benzamide;
or a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 wherein the mammal is a human.
3 . A method of treating or lessening the severity of cancer in a mammal in need thereof, which comprises administering to such mammal a therapeutically effective amount of the compound:
2-[(5-Chloro-2-{[3-methyl-1-(1-methylethyl)-1H-pyrazol-5-yl]amino}-4-pyridinyl)amino]-N-(methyloxy)benzamide;
or a pharmaceutically acceptable salt thereof.
4 . A method according to claim 3 wherein said cancer is selected from:
skin, breast, brain, cervical carcinomas, testicular carcinomas, astrocytic, colorectal, endometrial, esophageal, gastric, head and neck, hepatocellular, laryngeal, lung, oral, ovarian, prostate, thyroid carcinomas, sarcomas, lung, lymphomas, mesothelioma, Gastrointestinal, stomach, pancreas, small bowel, large bowel, kidney, bladder and urethra, liver, bone, Ewing's sarcoma, malignant lymphoma, multiple myeloma, malignant giant cell tumor chordoma, brain, glioblastoma multiform, spinal cord, uterus, cervical, ovarian, squamous cell carcinoma, and hematologic cancers.
5 . A method according to claim 4 wherein said cancer is brain cancer.
6 . A method according to claim 4 wherein said cancer is mesothelioma.
7 . A method according to claim 4 wherein said cancer is pancreatic cancer.